Statement of Changes in Beneficial Ownership (4)
March 05 2015 - 5:36PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
LAPALME PIERRE
|
2. Issuer Name
and
Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC
[
BMRN
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__
X
__ Director
_____ 10% Owner
_____ Officer (give title below)
_____ Other (specify below)
|
(Last)
(First)
(Middle)
C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE
|
3. Date of Earliest Transaction
(MM/DD/YYYY)
3/3/2015
|
(Street)
NOVATO, CA 94949
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock
|
3/3/2015
|
3/3/2015
|
M
|
|
10000
|
A
|
$11.15
|
40150
|
D
|
|
Common Stock
|
3/3/2015
|
3/3/2015
|
M
|
|
10000
|
A
|
$17.33
|
50150
|
D
|
|
Common Stock
|
3/3/2015
|
3/3/2015
|
S
|
|
20000
|
D
|
$106.57
(1)
|
30150
|
D
|
|
Common Stock
|
|
|
|
|
|
|
|
1500
|
I
|
Shares held by spouse
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code
(Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
|
8. Price of Derivative Security
(Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Stock Option (right to buy Common Stock)
|
$11.15
|
3/3/2015
|
3/3/2015
|
M
|
|
|
10000
|
7/27/2006
(2)
|
1/26/2016
|
Common Stock
|
10000
|
$0
|
0
(3)
|
D
|
|
Stock Option (right to buy Common Stock)
|
$17.33
|
3/3/2015
|
3/3/2015
|
M
|
|
|
10000
|
12/7/2007
(4)
|
6/6/2017
|
Common Stock
|
10000
|
$0
|
12500
(3)
|
D
|
|
Explanation of Responses:
|
(
1)
|
The price in column 4 is an average weighted price. The price actually received ranged from $106.20 to 106.895. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the amount of shares sold at each price within the range.
|
(
2)
|
Original option grant vests 6/48ths on July 27, 2006, and 1/48th on the 27th of each month thereafter.
|
(
3)
|
Reflects the number of stock options that remain outstanding from this specific stock option grant following the reported transaction.
|
(
4)
|
Original option grant vests 6/48ths on December 7, 2007, and 1/48th on the 7th of each month thereafter.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
LAPALME PIERRE
C/O BIOMARIN PHARMACEUTICAL INC.
105 DIGITAL DRIVE
NOVATO, CA 94949
|
X
|
|
|
|
Signatures
|
/s/ Laura Randall Woodhead, Attorney-in-Fact
|
|
3/5/2015
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 4(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
BioMarin Pharmaceutical (NASDAQ:BMRN)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioMarin Pharmaceutical (NASDAQ:BMRN)
Historical Stock Chart
From Sep 2023 to Sep 2024